| Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Hack Andrew A. F. | Director | May 18 | Buy | 3.35 | 211,268 | 707,262 | 8,087,400 | May 18 06:19 PM | | Hack Andrew A. F. | Director | May 17 | Buy | 3.18 | 3,440 | 10,952 | 7,876,132 | May 18 06:19 PM | | Hack Andrew A. F. | Director | May 16 | Buy | 3.10 | 135,292 | 419,446 | 7,872,692 | May 18 06:19 PM | | Carvajal Alejandra | Chief Legal Officer | Apr 26 | Option Exercise | 0.00 | 13,250 | 0 | 13,250 | Apr 28 05:23 PM | | Carvajal Alejandra | Chief Legal Officer | Apr 26 | Sale | 3.69 | 3,948 | 14,568 | 9,302 | Apr 28 05:23 PM | | Hack Andrew A. F. | Director | Apr 13 | Buy | 4.05 | 617,284 | 2,500,000 | 7,737,400 | Apr 14 04:59 PM | | Hack Andrew A. F. | Director | Apr 12 | Buy | 4.18 | 598,086 | 2,499,880 | 7,120,116 | Apr 13 06:27 PM | | Hack Andrew A. F. | Director | Feb 07 | Buy | 4.42 | 1,136,363 | 5,022,724 | 6,522,030 | Feb 08 05:04 PM | | Lowinger Timothy B | Chief Science & Tech Off. | Jan 18 | Sale | 5.92 | 4,741 | 28,067 | 131,234 | Jan 19 06:25 PM | | Mandelia Ashish | VP, Controller | Jan 18 | Sale | 5.92 | 1,982 | 11,733 | 3,371 | Jan 19 06:19 PM | | Hack Andrew A. F. | Director | Dec 30 | Buy | 6.15 | 815,000 | 5,012,250 | 5,385,667 | Jan 04 06:16 PM | | Hack Andrew A. F. | Director | Dec 29 | Buy | 5.75 | 875,000 | 5,031,250 | 4,570,667 | Jan 03 06:28 PM | | Lowinger Timothy B | Chief Science & Tech. Officer | Dec 20 | Option Exercise | 1.40 | 45,593 | 63,830 | 120,766 | Dec 20 05:01 PM | | Yang Arvin | Chief Medical Officer | Dec 01 | Sale | 6.81 | 5,527 | 37,639 | 12,973 | Dec 02 05:00 PM | | Lowinger Timothy B | Chief Science & Tech. Officer | Aug 20 | Option Exercise | 6.16 | 2,216 | 13,651 | 77,389 | Aug 24 04:31 PM | | Lowinger Timothy B | Chief Science & Tech. Officer | Aug 20 | Sale | 11.01 | 2,216 | 24,398 | 75,173 | Aug 24 04:31 PM | | Lowinger Timothy B | Chief Science & Tech. Officer | Jul 20 | Option Exercise | 6.16 | 2,227 | 13,718 | 77,400 | Jul 22 04:32 PM | | Lowinger Timothy B | Chief Science & Tech. Officer | Jul 20 | Sale | 12.11 | 2,227 | 26,969 | 75,173 | Jul 22 04:32 PM | | Lowinger Timothy B | Chief Science & Tech. Officer | Jul 19 | Sale | 12.02 | 8,496 | 102,122 | 75,173 | Jul 19 08:50 PM | | Kaufman Michael J. | Chief Manufacturing Officer | Jul 19 | Sale | 12.02 | 6,312 | 75,870 | 32,622 | Jul 19 08:50 PM | | Protopapas Anna | President & CEO | Jul 19 | Sale | 12.02 | 21,901 | 263,250 | 282,978 | Jul 19 08:49 PM | | Protopapas Anna | President & CEO | Jul 16 | Sale | 12.47 | 20,043 | 249,936 | 304,879 | Jul 19 08:49 PM | | Kaufman Michael J. | Chief Manufacturing Officer | Jul 16 | Sale | 12.47 | 5,776 | 72,027 | 38,934 | Jul 19 08:50 PM | | Lowinger Timothy B | Chief Science & Tech. Officer | Jul 16 | Sale | 12.47 | 7,775 | 96,954 | 83,669 | Jul 19 08:50 PM | | Lowinger Timothy B | CS & Technology Officer | Jul 08 | Option Exercise | 1.40 | 20,000 | 28,000 | 51,444 | Jul 09 05:25 PM | | Lowinger Timothy B | CS & Technology Officer | Jul 01 | Option Exercise | 3.52 | 1,886 | 6,644 | 33,330 | Jul 02 04:32 PM | | Lowinger Timothy B | CS & Technology Officer | Jul 01 | Sale | 13.60 | 1,886 | 25,650 | 31,444 | Jul 02 04:32 PM | | Lowinger Timothy B | Chief Science & Tech. Officer | Jun 21 | Option Exercise | 6.16 | 2,220 | 13,670 | 33,662 | Jun 23 04:30 PM | | Lowinger Timothy B | Chief Science & Tech. Officer | Jun 21 | Sale | 13.78 | 2,220 | 30,592 | 31,444 | Jun 23 04:30 PM | | Alleva Lawrence M | Director | Jun 01 | Buy | 14.38 | 1,035 | 14,883 | 2,120 | Jun 03 06:58 PM |
|
